Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.74Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: 21.88%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant clinical success and progress in regulatory alignment for iopofosine, alongside financial strengthening efforts. However, these positive aspects were countered by regulatory delays affecting the NDA submission, increased SG&A expenses, strategic restructuring, and compliance challenges with NASDAQ listing requirements.Company Guidance
During the call, Cellectar Biosciences provided guidance on several key metrics and future plans. The company reported a 98.2% clinical benefit rate, an 83.6% overall response rate, and a 58.2% major response rate from their CLOVER-WaM study for iapopacine I-131 in treating relapsed/refractory Waldenstrom's macroglobulinemia (WM). Financially, Cellectar ended 2024 with $23.3 million in cash and equivalents, up from $9.6 million at the end of 2023, and implemented a cost-saving restructuring to extend their cash runway into Q4 2025. They plan to initiate a Phase 3 study for iopofosine, aligning with the FDA on the study design for accelerated approval, estimating the trial to cost $40-$45 million and enroll 100 patients per arm. Additionally, their IND filings for CLR 121225 and CLR 121125 studies are planned, each costing around $4.5 million. They are also exploring non-dilutive funding options and licensing deals to support these initiatives.Impressive Clinical Outcomes in CLOVER-WaM Study
Iapopacine demonstrated a 98.2% clinical benefit rate, 83.6% overall response rate, and a major response rate of 58.2% in the treatment of relapsed/refractory Waldenstrom's macroglobulinemia.
Regulatory Progress for Iopofosine
Alignment achieved with FDA on the design of a Phase 3 study required for market approval, setting a clear path for NDA submission and market approval.
Financial Strengthening Efforts
Execution of multiple financial transactions, generating $44.1 million from warrant exercise and $19.4 million from inducement financing, increasing cash and cash equivalents to $23.3 million by the end of 2024.
Potential Non-Dilutive Funding and Market Opportunity
Ongoing evaluation of inbound collaborations and licensing deals for iapopacine, driven by its significant market potential.
Pipeline Expansion and Innovation
Advancement of alpha emitter for pancreatic cancer and Auger emitter for triple negative breast cancer, showcasing the versatility of the PDC platform.
---
CLRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $0.32 | $0.30 | -6.25% |
| Nov 18, 2024 | $1.86 | $1.77 | -4.84% |
| Aug 13, 2024 | $1.86 | $2.02 | +8.60% |
| May 14, 2024 | $3.06 | $3.18 | +3.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cellectar Biosciences (CLRB) report earnings?
Cellectar Biosciences (CLRB) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cellectar Biosciences (CLRB) earnings time?
Cellectar Biosciences (CLRB) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLRB EPS forecast?
CLRB EPS forecast for the fiscal quarter 2025 (Q1) is -0.16.
---